Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recommendations about new mammography technique for breast cancer screening in France

On March 17, 2023, the French National Authority for Health (HAS) published an update on its recommendations for techniques to be used within the organized breast cancer screening. HAS recommends introducing mammography by tomosynthesis in association with the reconstruction of a synthetic 2D image.

The National Cancer Institute (INCa) contacted HAS to assess the opportunity to introduce mammography by tomosynthesis (3D) into the organized screening strategy for breast cancer, which currently includes only authorized 2D digital mammography. In 2019 HAS carried out an initial analysis of the literature on the performance of mammography by tomosynthesis. This time, the HAS published an evaluation report on the performance and place of tomosynthesis mammography in the nationally organized breast cancer screening program – Part 2.

The HAS recommends integrating mammography by tomosynthesis associated with the reconstruction of a synthetic 2D image (3D + 2D) in organized screening for breast cancer, provided that it is systematically associated with the reconstruction of a synthetic 2D image. In parallel with the progressive deployment of 3D+2D in the organized screening throughout the national territory, the HAS recommends maintaining the current procedure based on digital mammography (2D). The HAS does not recommend the use of 3D alone. In addition, the HAS does not recommend the concomitant use of 3D and 2D, which increases exposure to X-rays.

See the details in French here

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.